Identification of steroid ligands able to inactivate the mineralocorticoid receptor harboring the S810L mutation responsible for a severe form of hypertension

Molecular and Cellular Endocrinology

Volumn 217, Issue 1-2, 2004, Pages 181-188

  Pinon, Grégory Maurice ^a   Fagart, Jérôme ^a   Souque, Anny ^a   Auzou, Gilles ^a   Vandewalle, Alain ^a   Rafestin Oblin, Marie Edith ^a  

^a INSERM   (France)

Author keywords

Aldosterone; Hypertension; Nuclear receptor

Indexed keywords

ASPARAGINE; GLUTAMINE; LEUCINE; LIGAND; MINERALOCORTICOID RECEPTOR; MUTANT PROTEIN; STEROID;

ANIMAL CELL; BINDING AFFINITY; BIOCHEMISTRY; COMPLEX FORMATION; CONFERENCE PAPER; CONFORMATION; CONTROLLED STUDY; DISEASE SEVERITY; GENE MUTATION; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN;

EID: 2342456441     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2003.10.053     Document Type: Conference Paper

References (23)

1. Auzou G., Fagart J., Souque A., Hellal-Levy C., Wurtz J.M., Moras D., Rafestin-Oblin M.E. A single amino acid mutation of ala-773 in the mineralocorticoid receptor confers agonist properties to 11beta-substituted spirolactones. Mol. Pharmacol. 58:2000;684-691
2. Bocchi B., Fagart J., Cluzeaud F., Fay M., Rafestin-Oblin M.E., Farman N. Glucocorticoid metabolism by 11-beta hydroxysteroid dehydrogenase type 2 modulates human mineralocorticoid receptor transactivation activity. J. Steroid Biochem. Mol. Biol. 84:2003;239-244
3. Bourguet W., Germain P., Gronemeyer H. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol. Sci. 21:2000;381-388
4. Cadepond F., Ulmann A., Baulieu E.E. RU486 (mifepristone): mechanisms of action and clinical uses. Annu. Rev. Med. 48:1997;129-156
5. Claire M., Faraj H., Grassy G., Aumelas A., Rondot A., Auzou G. Synthesis of new 11beta-substituted spirolactone derivatives. Relationship with affinity for mineralocorticoid and glucocorticoid receptors. J. Med. Chem. 36:1993;2404-2407
6. Claire M., Rafestin-Oblin M.E., Michaud A., Corvol P., Venot A., Roth-Meyer C., Boisvieux J.F., Mallet A. Statistical test of models and computerised parameter estimation for aldosterone binding in rat kidney. FEBS Lett. 88:1978;295-299
7. Corvol P., Claire M., Oblin M.E., Geering K., Rossier B. Mechanism of the antimineralocorticoid effects of spirolactones. Kidney Int. 20:1981;1-6
8. de Wet J.R., Wood K.V., De Luca M., Helinski D.R., Subramani S. Firefly luciferase gene: structure and expression in mammalian cells. Mol. Cell. Biol. 7:1987;725-737
9. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895
10. Fagart J., Wurtz J.M., Souque A., Hellal-Levy C., Moras D., Rafestin-Oblin M.E. Antagonism in the human mineralocorticoid receptor. EMBO J. 17:1998;3317-3325
11. Faraj H., Aumelas A., Claire M., Rondot A., Auzou G. Synthesis of new 10beta-propargylic and 11beta-allenic steroidal spirolactones. Steroids. 56:1991;558-561
12. Geller D.S., Farhi A., Pinkerton N., Fradley M., Moritz M., Spitzer A., Meinke G., Tsai F.T., Sigler P.B., Lifton R.P. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 289:2000;119-123
13. Gouilleux F., Sola B., Couette B., Richard-Foy H. Cooperation between structural elements in hormono-regulated transcription from the mouse mammary tumor virus promoter. Nucleic Acids Res. 19:1991;1563-1569
14. Hellal-Levy C., Couette B., Fagart J., Souque A., Gomez-Sanchez C., Rafestin-Oblin M. Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. FEBS Lett. 464:1999;9-13
15. Hellal-Levy C., Fagart J., Souque A., Wurtz J.M., Moras D., Rafestin-Oblin M.E. Crucial role of the H11-H12 loop in stabilizing the active conformation of the human mineralocorticoid receptor. Mol. Endocrinol. 14:2000;1210-1221
16. Herbomel P., Bourachot B., Yaniv M. Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma. Cell. 39:1984;653-662
17. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P. The nuclear receptor superfamily: the second decade. Cell. 83:1995;835-839
18. Moras D., Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell Biol. 10:1998;384-391
19. Rafestin-Oblin M.E., Couette B., Radanyi C., Lombes M., Baulieu E.E. Mineralocorticosteroid receptor of the chick intestine. Oligomeric structure and transformation. J. Biol. Chem. 264:1989;9304-9309
20. + absorption in mammalian principal cortical collecting duct cells. Mol. Pharmacol. 62:2002;1306-1313
21. Rafestin-Oblin M.E., Souque A., Bocchi B., Pinon G., Fagart J., Vandewalle A. The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related. Endocrinology. 144:2003;528-533
22. Ribeiro R.C., Kushner P.J., Baxter J.D. The nuclear hormone receptor gene superfamily. Annu. Rev. Med. 46:1995;443-453
23. Warriar N., Yu C., Govindan M.V. Hormone binding domain of human glucocorticoid receptor. Enhancement of transactivation function by substitution mutants M565R and A573Q. J. Biol. Chem. 269:1994;29010-29015